Loading…
Orthofix Medical Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in OFIX.
▼ -73.8% over 5Y.
today you would have $247.64▼ -75.2%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 17 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $15.16 | $17.46 | $13.48 | $20.53 | $31.09 | $42.98 | $46.18 | $52.49 | $54.70 | $36.18 | $39.21 | $30.06 | $22.82 | $39.33 | $35.23 | $29.00 | $30.93 | |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| LRMRLarimar Therapeutics, Inc. | $3.82 | — | 3.1x | — | -139.63% | $396.83M |
| MYGNMyriad Genetics Inc | $4.17 | — | 1.3x | — | -32.54% | $398.86M |
| XFORX4 Pharmaceuticals, Inc | $4.04 | 2.9x | 2.5x | — | -113.08% | $400.55M |
| AUNAAUNA S.a | $5.18 |
Orthofix Medical Inc., together with its subsidiaries, operates as a medical technology company in the United States, Italy, the United Kingdom, France, Germany, Brazil, and internationally. It operates through two segments, Global Spine and Global Limb Reconstruction. The Global Spine segment manufactures, distributes, and provides support services for bone growth stimulation devices that enhance bone fusion; designs, develops, and markets a portfolio of spine fixation implant products for use throughout the spinal column; and offers bone graft substitutes, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers in various forms with supporting graft delivery solutions to treat various spinal, orthopedic, and dental conditions. This segment also designs, develops, and markets a portfolio of navigation technologies, including tracked surgical tools, intelligent software, and imaging equipment based on machine-vision and optical innovations; and 7D FLASH Navigation System, a navigation platform for spinal and cranial procedures. The Global Limb Reconstruction segment offers products and solutions for the underserved limb reconstruction market, including deformity correction, limb lengthening, complex fracture management, and limb preservation. This segment also designs, develops, and markets external and internal fixation limb reconstruction products that are coupled with enabling digital technologies to support the entire patient care continuum. It sells its products through distributors and sales representatives to hospitals, healthcare organizations, healthcare providers, ambulatory surgery centers, and out-patient hospitals. The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in July 2018. Orthofix Medical Inc. was founded in 1980 and is headquartered in Lewisville, Texas.
Company description provided by Yahoo Finance.
| P/E |
| 21.8x |
| — |
| — |
| — |
| — |
| — |
| 330.6x |
| — |
| 72.9x |
| 160.9x |
| 212.8x |
| — |
| — |
| — |
| 17.8x |
| — |
| 11.7x |
| 21.8x |
| P/S | 1.5x | 0.7x | 0.9x | 0.7x | 1.6x | 1.3x | 2.1x | 1.9x | 2.2x | 2.3x | 1.6x | 1.8x | 1.4x | 1.0x | 1.7x | 1.5x | 1.1x | 1.0x |
| P/B | 2.2x | 1.4x | 1.4x | 0.8x | 2.2x | 1.8x | 2.4x | 2.7x | 3.0x | 3.4x | 2.5x | 2.5x | 1.9x | 1.4x | 2.1x | 2.4x | 1.7x | 2.2x |
| EPS | -$2.33 | -$3.30 | -$4.12 | -$0.98 | -$1.95 | $0.13 | -$1.51 | $0.72 | $0.34 | $0.17 | -$0.15 | -$0.46 | -$1.54 | $2.21 | -$0.97 | $2.47 | $1.42 |
| Profit margin | -2.12% | -11.21% | -15.76% | -20.28% | -4.29% | -8.26% | 0.62% | -6.19% | 3.05% | 1.43% | 0.75% | -0.71% | -2.12% | -7.25% | 9.73% | -4.06% | 9.58% | 4.49% |
| ROE | -2.85% | -20.49% | -25.04% | -25.29% | -5.86% | -11.39% | 0.71% | -8.69% | 4.12% | 2.10% | 1.16% | -0.97% | -2.85% | -9.74% | 12.02% | -6.31% | 14.72% | 10.19% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| 86.3x |
| 0.7x |
| — |
| 1.62% |
| $383.61M |
| TKNOAlpha Teknova, Inc. | $7.12 | — | 5.5x | — | -24.19% | $382.26M |
| RLMDRelmada Therapeutics Inc | $3.78 | — | 0.4x | — | -55.66% | $403.21M |